Tag: Seagen
Phase 3 EV-302 clinical trial : Seagen, Astellas reveal promising for PADCEV and KEYTRUDA combo
Seagen Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase 3 EV-302 clinical trial, presenting PADCEV in combination with KEYTRUDA versus chemotherapy. ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More